@article{APM23104,
author = {David D. Wilson and Clayton E. Alonso and Austin J. Sim and Travis Peck and Lydia L. Handsfield and Quan Chen and Leslie Blackhall and Timothy N. Showalter and Kelli A. Reardon and Paul W. Read},
title = {STAT RT: a prospective pilot clinical trial of Scan-Plan-QA-Treat stereotactic body radiation therapy for painful osseous metastases},
journal = {Annals of Palliative Medicine},
volume = {8},
number = {3},
year = {2018},
keywords = {},
abstract = {Background: Planning and treatment of bone metastases with palliative radiotherapy often requires 1–3 weeks, resulting in patient inconvenience and delayed palliation. We developed an expedited workflow that delivers palliative stereotactic body radiation therapy (SBRT) to painful bone metastases in which CT, planning, quality assurance (QA), and initial treatment are performed one day. This prospective pilot clinical trial evaluates the feasibility, safety, efficacy, and patient satisfaction of this workflow.
Methods: Patients with 1–3 painful bone metastases were prospectively enrolled and treated with 2–5 fractions of 5–10 Gy per fraction. Bone pain, opioid use, patient satisfaction, performance status, and quality of life were evaluated prior to and at 1, 4, 8, 12, 26, and 52 weeks post treatment. Outcomes and treatment-related toxicity were analyzed.
Results: Twenty-eight patients were enrolled and 37 metastases treated, receiving an average of 21.6 Gy in 3.1 fractions. Median time from CT simulation to 1st treatment was 6.6 hours. Average worst pain scores were significantly lower at all post-treatment time points with maximal response noted at 3 months. Opioid use was not significantly different from baseline at any follow up. Performance status was significantly increased only at week 12. Bone pain quality of life was significantly increased at all time points except at 52 weeks while general quality of life was significantly increased at only weeks 8 and 26. Ninety-two percent of patients reported being mostly or completely satisfied with the treatment results from week 8 until the end of follow-up. There was no grade 3 or higher toxicities.
Conclusions: Results demonstrate that treating bone metastases with palliative SBRT via a multi-fraction Scan-Plan-QA-Treat patient centric workflow is feasible and safe. Although performance status, general quality of life, and opioid use were not significantly altered, patient satisfaction was high with this same-day treatment workflow.},
issn = {2224-5839}, url = {https://apm.amegroups.org/article/view/23104}
}